In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...Read More
Current stage-Stage IV (Advanced) Posts on Medivizor
In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...Read More
What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?
In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...Read More
In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...Read More
Is changing treatment intensity after PET scan effective for patients with advanced stage Hodgkin lymphoma?
In a nutshell This study looked at changing treatment intensity after a PET scan for patients with advanced stage Hodgkin lymphoma. The authors concluded that reducing treatment intensity for patients with a negative PET scan can reduce negative side effects and improve long-term outcomes. Some background Advanced stage Hodgkin lymphoma (HL) can...Read More
Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma
In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...Read More
Combining bendamustine and rituximab improves time to disease progression in follicular and mantle-cell lymphomas
In a nutshell This study examined the use of the combination of bendamustine (Treanda) and rituximab (Rituxan) as a firstline treatment in patients with follicular or mantle cell lymphoma. This study concluded that this treatment combination was more effective than the standard treatment of rituximab plus CHOP chemotherapy. Some background The...Read More
In a nutshell This study compared different chemotherapy regimens and rituximab (Rituxan) for the initial treatment of advanced follicular lymphoma. This study concluded that the combinations R-CHOP and R-FM were more effective than R-CVP. R-CHOP was associated with fewer severe side effects than R-FM. Some background Follicular lymphoma (FL) is...Read More
In a nutshell This study assessed the effectiveness of using escalated BEACOPP plus rituximab chemotherapy in patients with advanced stage Hodgkin Lymphoma. The study concluded that adding rituximab to the standard escalated BEACOPP regimen did not significantly improve time to disease progression. Some background Hodgkin Lymphoma (HL) is...Read More
In a nutshell This review discussed the current and future treatment options for advanced Hodgkin lymphoma (stage III or IV). Some background While early-stage Hodgkin lymphoma has very high remission rates, rates for advanced disease are generally lower. The standard treatment option for advanced Hodgkin lymphoma is ABVD chemotherapy...Read More
In a nutshell This study compared three chemotherapy combinations, standard dose BEACOPP, increased dose BEACOPP, and COPP-ABVD, for advanced Hodgkin lymphoma. The authors concluded that increased-dose BEACOPP was more effective. Some background The standard chemotherapies for advanced Hodgkin lymphoma (stage III or IV or those with additional...Read More